Clinical Scenarios: Matching Regimen to Patient Profile

Two clinical scenarios illustrated shared decision-making in practice: a 58-year-old woman with TP53 mutation, L858R, and asymptomatic brain metastases drew unanimous consensus for treatment intensification with either FLAURA2 or MARIPOSA, given her high-risk features and flexible schedule. A 52-year-old active man with no brain metastases, undetectable ctDNA, and a preference for quality of life sparked debate, with Team Thriller favoring osimertinib-chemotherapy for its proven OS benefit and simpler supportive care, whereas Team Purple Reign argued that patient-defined quality of life and willingness to manage prophylaxis should guide the choice, underscoring that shared decision-making, not assumptions, should drive regimen selection. Team Thriller was awarded the night's trophy.